【花旗:巨子生物(02367.HK)第3季复苏步伐将更为关键 维持“买入”评级】智通财经APP获悉,花旗发布研报称,巨子

智通财经
25 Jun
【花旗:巨子生物(02367.HK)第3季复苏步伐将更为关键 维持“买入”评级】智通财经APP获悉,花旗发布研报称,巨子生物(02367.HK)于6月24日的业绩电话会中定下了积极基调,维持2025年目标不变。且管理层有信心在2025年下半年弥补618促销活动期间短期挫折带来的损失。花旗认为,618活动结束后,KOL合作的恢复以及产品退货的正常化是初步的积极迹象,而2025年第3季对于衡量复苏步伐将更为关键。该行结束对其30天的负面催化剂观察,维持“买入”评级,并下调集团估价及目标价。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10